Effect of paroxetine on neurological function and psychological state in patients with depression after acute ischemic stroke

Table 1 Baseline data of two groups, mean ± SD

Indicators	Control group (n = 52)	Research group (n = 54)	χ2	P value
Age (years)	51.48 ± 7.95	51.70 ± 7.96	0.142	0.887
Sex (male/female)	28/24	33/21	0.572	0.757
Disease course (months)	9.19 ± 1.70	8.74 ± 2.44	1.098	0.275
Body mass index (kg/m2)	23.08 ± 2.37	22.28 ± 2.20	1.802	0.074
Diabetes mellitus (with/without)	10/42	8/46	0.366	0.545
Hypertension (with/without)	18/34	17/37	0.118	0.732
Coronary heart disease (with/without)	6/46	10/44	1.007	0.316

Table 2 Clinical efficacy of the two groups, n (%)

Indicators	Control group (n = 52)	Research group (n = 54)	χ2	P value
Cure	10 (19.23)	14 (25.93)
Marked effectiveness	13 (25.00)	20 (37.04)
Effectiveness	12 (23.08)	12 (22.22)
Ineffectiveness	17 (32.69)	8 (14.81)
Effective rate	35 (67.31)	46 (85.19)	4.698	0.030

Table 3 Incidence rate of adverse events in two groups, n (%)

Indicators	Control group (n = 52)	Research group (n = 54)	χ2	P value
Dry mouth	2 (3.85)	0 (0.00)
Loss of appetite	3 (5.77)	1 (1.85)
Headache	2 (3.85)	1 (1.85)
Insomnia	4 (7.69)	2 (3.70)
Total	11 (21.15)	4 (7.41)	4.121	0.042